The venture capital company Ysios Capital, a member of CATALONIA.HEALTH, has announced that its investee company, ReproNovo has closed a $65 milions Series A financing round. The round, with a strong support from Ysios, was led by Jeito Capital, co-led by AXA IM Alts and founding investor M Ventures, and ALSA Ventures. ReproNovo plans to use the proceeds to advance its pipeline of multiple Phase 2 programs.
ReproNovo is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. The company brings a proven track record in successful clinical development and commercial launches. Since its inception, ReproNovo has rapidly built a pipeline comprising two Phase 2 clinical-stage assets across three disease areas. With its lead candidate, RPN-001 (leflutrozole), the company will focus on the development of an orally administered therapy for infertility in men with low serum testosterone.
This transaction marks the sixteenth and latest investment by Ysios BioFund III, which has backed some of Europe's most innovative companies in areas such as oncology, rare diseases, neuroscience and now also reproductive health.
Guillem Laporta, Partner of Ysios Capital and head of the investment, explained: “This investment represents a double commitment for Ysios Capital: on the one hand, we are entering a new area for us, the treatment of infertility, and on the other, we are focusing on male infertility, a growing and still under-recognised problem in reproductive health. We are convinced that ReproNovo is the best company to take this step, due to the experience of its team and the clinical maturity of its programmes.”
Comments